• Risks of cancers related to smoking in families with CDKN2A mutations

      High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. Two research groups within GenoMEL have looked at the risk of cancers other than melanoma in families with inherited mutations in the p16 or CDKN2A gene: a group in Stockholm Sweden and another in Leiden, the Netherlands. WeRead More
  • Predictive Biomarker Research

    A predictive biomarker is a test which provides information for medical teams and patients about how likely a particular treatment is to benefit that patient and or the risk of side effects. Using predictive biomarkers is an important part of the aim to deliver “personalised medicine”.  That is, thatRead More
  • The second UK Melanoma Patient Conference

    A summary by Professor Julia Newton-Bishop The second Melanoma Patient Conference took place in Birmingham this year on June 16th and 17th. It was expertly organised (as was the first ever conference) by Imogen Cheese. It was very well attended by people who have experienced melanoma themselves or inRead More
  • How we in Leeds access on-going healthcare data about our research participants

      The following information is provided for participants who consented to long-term follow up using information provided by Cancer Registries and the Office of National Statistics (ONS) as part of these studies:   The Melanoma Follow-Up and Case-Control Family Study. Ethics Committee number: MREC 01/3/057 A Genetic Epidemiological StudyRead More
  • Launch of Patient Decision Aid

    Melanoma Focus (http://www.melanomafocus.com) has launched its Patient Decision Aid (PDA), whose aim is to inform people about melanoma and guide patients through the decisions they will need to take during their treatment. By helping people to understand their options, this new online tool should improve the effectiveness of conversations betweenRead More
  • Could you give 15 minutes of your time and a blood sample to help our research?

    Are you based in Leeds? We are a melanoma research group led by Professor JA Newton-Bishop and we aim to develop a blood test that measures immune function. We are doing this by comparing the genetic information in the immune cells of individuals who have illnesses that affect the immune system such as cancerRead More
  • Option Grids: information for melanoma patients

    NICE has worked with Option Grid and UK dermatologists Jason Thomson and Jane McGregor, to produce information for melanoma patients and their medical teams. The information is provided in the form of Option Grids which allow consideration of the potential advantages and disadvantages of given medical procedures or treatments.Read More
  • BAP1: a newly recognised melanoma gene

    GenoMEL has some new information in the Information for Patients section, on a rare inherited genetic mutation which increases the risk of melanoma in some families. The appearance of the moles and the melanomas in these families can be unusual and affected families are also at increased risk ofRead More
  • NICE Clinical Melanoma Guideline

    NICE published the Clinical Melanoma Guideline in July 2015. This Guideline is directed at secondary and tertiary care (hospital treatment) in the UK and considers the role of treatments such as sentinel node biopsy. This is a link to the guideline http://www.nice.org.uk/guidance/ng14 The Guideline addressed the role of sentinel nodeRead More

 

Julia Newton-Bishop, University of Leeds